Kalvista Pharmaceuticals Stock News

Goldman Sachs Group Inc. reduced its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 42.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,610 shares of the specialty pharmaceutical companys stock after selling 22,989 shares during the period. Goldman Sachs []

Metropolitan Life Insurance Co NY boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 100,660.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,038 shares of the specialty pharmaceutical companys stock after buying an additional 5,033 []

Marshall Wace LLP decreased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 54.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,996 shares of the specialty pharmaceutical companys stock after selling 20,447 shares during the period. Marshall Wace LLP owned []

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned an average rating of Buy from the seven analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have []

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat

CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commerc

The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content:   Ka

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV #EAACI2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, developmen

KalVista Pharmaceuticals, Inc. (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.